Builder's remedy lawsuits allow real estate developers to seek court approval to bypass local zoning laws and build higher-density residential projects – as long as they provide a certain number of affordable housing units. Politics & Government Lawsuit Over Affordable Housing In West Orange Sparks Political Shoving Match Between Council, Mayor A "builder's remedy" suit has been filed involving the site of a former wedding venue in West Orange. Here's what we know so far. A "builder's remedy" lawsuit was re ...

The Complaint alleges that Defendants misled investors concerning Capricor's lead cell therapy candidate drug deramiocel for the treatment of cardiomyopathy associated with DMD. Defendants gave the false impression that they could obtain first approval for DMD cardiomyopathy, while, at the same time, concealing material adverse facts concerning its four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel. The Complaint further that on July 11, 2025, Capricor issued a press releas ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Compass (CODI) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Compass between May 1, 2024, to May 7, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder righ ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Biohaven (BHVN) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Biohaven between March 24, 2023 and May 14, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholde ...

SAN DIEGO, July 17, 2025 (GLOBE NEWSWIRE) -- Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between October 9, 2024 and July 10, 2025. Capricor is a clinical-stage biotechnology company that engages in the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Vestis Corporation during the specified class period of the upcoming lead plaintiff deadline on August 8, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Vestis securities between May 2, 2024, and May 6, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the August 8, 2025 deadline [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3]. Group 3: Case Allegations - The lawsuit alleges that Vestis Corporation provided misleading statements about its business growth potential while concealing material adverse facts regarding its ability to execute strategic initiatives aimed at improving customer experience and revenue growth [4]. - When the true state of affairs became known, investors reportedly suffered damages [4].

SAN DIEGO, July 17, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Biohaven Ltd. (NYSE: BHVN) securities between March 24, 2023 and May 14, 2025. Biohaven is a biopharmaceutical company that discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology. The Company is developing, among other product candidates, troriluzole for the treatment of spinocerebellar ataxia (“SCA”), amo ...

ATLANTA, July 17, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information concerning Capricor’s four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel. If you purchased shares of Capricor between October 9, 2024 and July 10, 2025, and experienced ...

SAN DIEGO, July 17, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired UroGen Pharma Ltd. (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025. UroGen engages in the development and commercialization of solutions for specialty cancers. The Company’s lead pipeline product is UGN-102 (mitomycin), an intravesical solution intended to treat low-grade intermediate risk non-muscle invasive bladder cancer. F ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DoubleVerify Holdings, Inc. common stock during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][3]. Group 1: Class Action Details - Investors who bought DoubleVerify common stock between November 10, 2023, and February 27, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by July 21, 2025 [3]. Group 2: Case Allegations - The lawsuit alleges that DoubleVerify made false and misleading statements regarding its business operations, including the shift of customers' ad spending to closed platforms where DoubleVerify's capabilities were limited [5]. - It is claimed that the development of technology for closed platforms was more expensive and time-consuming than disclosed, impacting the monetization of DoubleVerify's high-margin advertising optimization services [5]. - The lawsuit also states that DoubleVerify's competitors were better positioned to incorporate AI into their offerings, adversely affecting DoubleVerify's competitive edge and profits [5]. - Additional allegations include systematic overbilling of customers for ad impressions served to declared bots and misleading risk disclosures that characterized adverse facts as mere possibilities [5].